India, May 12 -- Eikon Therapeutics Inc. (EIKN), a late-stage biopharmaceutical company, on Monday released its first quarter financial results, and provided clinical updates.
Q1 2026:
The company recorded a net loss of $83 million in Q1 2026, while in the same period of 2025, the net loss was $74.5million.
Research and development expenses (R&D) were $70 million, a 24% increase from the $56.6 million reported in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $596 million. The available capital is expected to fund company operations till 2027.
Clinical Updates:
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
EIK1001 is a dual-agonist of Toll-lik...